http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107188953-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-605 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-605 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-16 |
| filingDate | 2017-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-107188953-B |
| titleOfInvention | Glucagon-like peptide-1 analogs and uses thereof |
| abstract | The invention discloses a glucagon-like peptide-1 analogue and application thereof. The general formula of the amino acid sequence of the glucagon-like peptide-1 analogue provided by the invention is as follows: xaa 1 ‑Ser‑Glu‑Gly‑Thr‑Phe‑Xaa 7 ‑Ser‑Asp‑Xaa 10 ‑Ser‑Xaa 12 ‑Xaa 13 ‑Xaa 14 ‑Xaa 15 ‑Xaa 16 ‑Xaa 17 ‑Xaa 18 ‑Xaa 19 ‑Xaa 20 ‑Xaa 21 ‑Phe‑Xaa 23 ‑Xaa 24 ‑Trp‑Leu‑Xaa 27 ‑Xaa 28 ‑Xaa 29 ‑Xaa 30 . The invention replaces the amino acid at the second position of GLP-1 with Ala to Ser and changes the amino acid at other positions, so that the glucagon-like peptide-1 analogue has the biological functions of GLP-1 and GIP, the dosage of the analogue is reduced, and the hypoglycemic effect is realized. |
| priorityDate | 2017-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 188.